Picture of Evoke Pharma logo

EVOK — Evoke Pharma News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Evoke Pharma Inc reports results for the quarter ended in June - Earnings Summary

* Evoke Pharma Inc  EVOK.OQ  reported a quarterly adjusted
loss
of 71 cents​​ per share for the quarter ended in June. The lone
analyst forecast for the quarter was for a loss of 60 cents per
share.
    * Revenue rose 95.2% to $462.00 thousand from a year ago;
analysts
expected $580.00 thousand. 
    * Evoke Pharma Inc's reported EPS for the quarter was a loss
of 71
cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Evoke Pharma Inc shares had fallen by 3.1% this
quarter and
lost 52.4% so far this year.
    * The company reported a quarterly loss of $2.23 million.
    * Wall Street's median 12-month price target for Evoke
Pharma Inc
is $78.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.60          -0.71          Missed
 Mar. 31 2022      -0.48          -0.84          Missed
 Dec. 31 2021      -0.96          -0.72          Beat
 Sep. 30 2021      -0.84          -0.72          Beat

Recent news on Evoke Pharma

See all news